Global Nasal Spray Market Expected to Reach $30.7 Billion by 2035 Amid Asthma Cases
Nasal spray market was valued at $14.8 billion in 2025 and is projected to reach $30.7 billion by 2035, growing at a CAGR of 7.6% during the forecast period (2026-2035). The global nasal spray market experienced substantial growth, driven by the rising prevalence of respiratory disorders, particularly asthma. Asthma, a chronic inflammation of the lung airways, caused symptoms such as coughing, wheezing, chest tightness, and shortness of breath, affecting millions worldwide. By 2025, an estimated 280 million individuals were living with asthma, with urbanization, air pollution, and modern lifestyle factors contributing significantly to this increase. In the US, approximately 24.9 million individuals, or 7.7% of the population, had asthma by 2025, with adults accounting for 20.2 million of the total. Prevalence was higher among adults (8.0%) than children (6.5%) and disproportionately affected females (9.7%) compared to males (6.2%). Asthma patients accounted for over 900,000 emergency department visits and 94,000 hospital inpatient stays annually, imposing an economic burden estimated at $50 billion. More than 3,500 fatalities occurred each year due to asthma, with older adults being the most affected.
Browse the full report description of “Nasal Spray Market Size, Share & Trends Analysis Report by Product Type (Corticosteroids, Antihistamines, Decongestants, Saline Sprays, and Others (Anticholinergics, Cromolyn)) and Application (Asthma, COPD, Allergic Rhinitis and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies and Online Pharmacies), Forecast (2026-2035)” at https://www.omrglobal.com/industry-reports/nasal-spray-market
Approximately half of all asthma patients experienced at least one attack annually, highlighting the need for effective management solutions. In India, around 35 million individuals were affected by asthma, representing 13.09% of the global burden and underscoring the market potential in emerging economies. Rising disease prevalence, coupled with the convenience and efficacy of nasal spray therapies, fueled demand in both developed and developing regions. Innovations in drug delivery, targeted formulations, and over-the-counter accessibility further bolstered market expansion. Consequently, nasal sprays were increasingly recognized as a frontline therapy, driving sustained growth in the global respiratory care segment.
Strategic Product Launches and Innovation Driving Competitive Expansion
The global nasal spray market includes several established pharmaceutical and consumer healthcare companies such as Bayer AG, Haleon plc, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc. These players maintain a strong presence through diversified product offerings, established brands, and extensive global distribution capabilities across both prescription and over-the-counter segments. Key companies are focusing on expanding their product portfolios, securing regulatory approvals, and strengthening their presence in high-growth regions.
- In July 2025, Lupin Ltd., launched Ipratropium Bromide Nasal Solution (Nasal Spray) in 0.03% and 0.06% strengths in the United States, following approval as a bioequivalent to Atrovent Nasal Spray. The product is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic rhinitis, as well as the common cold across pediatric and adult populations. The reference product recorded estimated annual US sales of approximately $63 million as of May 2025.
- In October 2023, Haleon launched Otrivin Nasal Mist, a next-generation nasal spray developed in collaboration with Aptar Pharma, featuring microdroplet technology for improved drug delivery and user comfort. The product incorporates a proprietary Lateral Control System pump that enables a single-button mist release and more ergonomic usage compared to conventional sprays. Initially introduced in select European markets, the spray is designed to address nasal congestion associated with colds, allergic rhinitis, and sinusitis, with broader global rollout planned.
Market Coverage
- The market number available for – 2025-2035
- Base year- 2025
- Forecast period- 2026-2035
- Segment Covered-
- Pet
- Ingredients
- Source
- Form
- Competitive Landscape – Bayer AG, Haleon plc, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc., among others.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Nasal Spray Market Report Segment
By Product Type
- Corticosteroids
- Antihistamines
- Decongestants
- Saline Sprays
- Others (Anticholinergics, Cromolyn)
By Application
- Asthma
- COPD
- Allergic Rhinitis
- Others
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Global Nasal Spray Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- ASEAN Economies
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/nasal-spray-market